Dear:

OLUX® (clobetasol propionate) Foam, 0.05% and OLUX-E™ (clobetasol propionate) Foam, 0.05% are now available together as the OLUX/OLUX-E Complete Pack, which includes:

- OLUX 100 g with VersaFoam-HF™, a hydroethanolic foam vehicle that delivers efficacy where needed
- OLUX-E 10 g with VersaFoam-EF™, an emulsion vehicle delivering efficacy with moisturizing properties

OLUX/OLUX-E Complete Pack NDC # 00145-2300-03

Wholesaler	**Item Number**
Cardinal	4057865
McKesson	2123354
ABC	410840
Kinray	239350
HD Smith	2138782
Morris Dixon	845255
Bellco	267506

About OLUX Foam:

- Patient-preferred foam vehicle[1]
- Disappears quickly with minimal residue[1]
- Penetrates better than clobetasol solution in vitro[2]

About OLUX-E Foam:

- Ethanol-free emollient formulation
- Class 1 efficacy across different types of dermatoses
- Safe and effective for patients age 12 and older

Please see important safety information on next page.

IMPORTANT SAFETY INFORMATION

OLUX Foam is indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of non-scalp regions excluding the face and intertriginous areas. OLUX Foam is not recommended for use in children under 12 years of age.

In clinical trials, the most common adverse events associated with the use of OLUX Foam were burning, dryness, and other reactions at the application site.

OLUX-E Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older.

The pooled incidence of local adverse reactions in trials for moderate to severe atopic dermatitis and mild to moderate plaque-type psoriasis with OLUX-E Foam was 1.9% for application site atrophy and 1.6% for application site reaction.

Treatment with OLUX Foam or OLUX-E Foam beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

Please see accompanying full Prescribing Information.

If you have any questions, please call us at 800-572-3225.

Sincerely,

Michelle Barrineau
Product Manager, OLUX/OLUX-E Complete Pack

References: 1. Data on file, August C. Stiefel Research Institute, Inc. **2.** Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. *Int J Dermatol*. 2000;39:535-538.

Stiefel Laboratories, Inc.
Corporate Headquarters
255 Alhambra Circle, Coral Gables, FL 33134
Tel 305-443-3800 • Fax 305-443-3467
www.stiefel.com

Stiefel Laboratories, Inc.
US Sales and Marketing
6340 Sugarloaf Parkway, Suite 400,
Duluth, GA 30097
Tel 770-945-0101 • Fax 770-945-5424